Despite its potential, targeting ASCT2 presents several challenges. One major challenge is the potential toxicity to normal tissues, as ASCT2 is also expressed in various healthy cells. Another challenge is the metabolic flexibility of cancer cells, which may adapt to the inhibition of ASCT2 by upregulating alternative amino acid transporters or metabolic pathways. Therefore, a combination of ASCT2 inhibitors with other therapeutic strategies may be required to achieve optimal outcomes.
